Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab

Abstract Background The development of pulmonary immune-related adverse events (irAEs) in patients undergoing PD-(L)1 targeted checkpoint inhibitors are rare, but may be life-threatening. While many published articles and guidelines are focusing on the presentation and upfront treatment of pulmonary...

Full description

Bibliographic Details
Main Authors: Guacimara Ortega Sanchez, Kathleen Jahn, Spasenija Savic, Alfred Zippelius, Heinz Läubli
Format: Article
Language:English
Published: BMJ Publishing Group 2018-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune checkpoint inhibitor
Cancer immunotherapy
Pneumonitis
Lung
Immune-related adverse event
Online Access:http://link.springer.com/article/10.1186/s40425-018-0400-4

Internet

http://link.springer.com/article/10.1186/s40425-018-0400-4

Similar Items